Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To report preliminary results on safety and tolerability of intravitreal injection of
Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green
(ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.